STENT registry safety data favors TAXUS(R) over Cypher(R) in the most complex diabetic patients
12 März 2006 - 10:26PM
PR Newswire (US)
Complex insulin-treated diabetic population shows numerical trend
toward improved MACE outcomes with TAXUS versus Cypher VANCOUVER,
March 12 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPI; TSX:ANP) today announced that its corporate partner
Boston Scientific Corporation ("BSC") today welcomed results from
the independent, multi-center STENT registry, the largest
prospective, comparative real world drug-eluting stent study ever
reported. The study included follow-up on 5,566 patients at eight
coronary centers in the United States who received either a
TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system or a
Cypher(R) Stent system, including 1,182 diabetic patients, nearly
500 of whom were insulin- treated diabetics. Among insulin-treated
diabetics, the results demonstrated a numerical trend toward
improved survival and lower overall Major Adverse Cardiac Events
(MACE) rate for patients who received a TAXUS stent system versus
those who received a Cypher stent system. The results were
presented at the American College of Cardiology's (ACC) inaugural
"Innovation in Intervention: the i2 Summit" in Atlanta. Among the
study's diabetic patients, the TAXUS stent system was used in more
complex lesions. The TAXUS patients had a slightly higher ACC risk
score, smaller vessels and longer lesions than Cypher patients.
Despite the higher complexity of the TAXUS patients, the results
favored the TAXUS stent system over the Cypher stent system in each
of the study's MACE categories for insulin-treated diabetics. The
MACE rate was a composite of death (2.1 percent for TAXUS versus
5.7 percent for Cypher), myocardial infarction (MI, or heart
attack) (1.3 percent for TAXUS versus 1.9 percent for Cypher), and
target vessel revascularization (TVR) (3.4 percent for TAXUS versus
4.2 percent for Cypher). The overall MACE rate also trended in
favor of TAXUS (6.0 percent versus 10.7 percent for Cypher). "In
insulin-treated diabetics there is a slight separation in outcomes
favoring the TAXUS stent system, although this did not reach
statistical significance," said Charles Simonton, M.D., chairman of
the executive steering committee for the STENT registry. "We plan
continued enrollment to further investigate this apparent
difference in outcomes." "Previous studies have confirmed that
paclitaxel and sirolimus have different mechanisms of action, and
this study provides additional favorable data regarding the
performance of paclitaxel in the treatment of insulin- treated
diabetics," said Paul LaViolette, Chief Operating Officer of Boston
Scientific. "These data provide further support for our belief that
the TAXUS stent system should be the preferred choice for the
treatment of complex lesions." STENT (Strategic Transcatheter
Evaluation of New Therapies) is the first U.S., multi-center,
prospective registry initiated to evaluate the long-term efficacy
and safety of paclitaxel- and sirolimus-eluting coronary stents
among real-world patients and clinical situations. BSC acquired
worldwide exclusive rights from Angiotech to use paclitaxel to coat
its coronary stent products and has co-exclusive rights to other
vascular and non-vascular products. About Angiotech Pharmaceuticals
Vancouver-based Angiotech Pharmaceuticals, Inc. is a specialty
pharmaceutical company pioneering the combination of pharmaceutical
compounds with medical devices and biomaterials to both create
novel solutions for poorly addressed disease states and improve
surgical outcomes. To find out more about Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please
visit our website at http://www.angiotech.com/. Statements
contained herein that are not based on historical or current fact,
including without limitation statements containing the words
"anticipates," "believes," "may," "continue," "estimate,"
"expects," and "will" and words of similar import, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, events or developments
to be materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Such factors include, among others, the following:
general economic and business conditions, both nationally and in
the regions in which the Company operates; technology changes;
competition; changes in business strategy or development plans; the
ability to attract and retain qualified personnel; existing
governmental regulations and changes in, or the failure to comply
with, governmental regulations; liability and other claims asserted
against the Company; and other factors referenced in the Company's
filings with the United States Securities and Exchange Commission
or the Canadian securities regulators. Given these uncertainties,
readers are cautioned not to place undue reliance on such
forward-looking statements. The Company does not assume the
obligation to update any forward-looking statements. FOR ADDITIONAL
INFORMATION: Analysts and Investors: Rui Avelar, Chief Medical
Officer Angiotech Pharmaceuticals, Inc. (604) 221-7676 ext 6933
Media: Colleen Beauregard Waggener Edstrom Bioscience (503)
443-7863, Email: DATASOURCE: Angiotech Pharmaceuticals, Inc.
CONTACT: Analysts and Investors: Rui Avelar, Chief Medical Officer,
Angiotech Pharmaceuticals, Inc., (604) 221-7676 ext 6933; Media:
Colleen Beauregard, Waggener Edstrom Bioscience, (503) 443-7863,
Email:
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024